Less Ads, More Data, More Tools Register for FREE

Pin to quick picksScience Group Regulatory News (SAG)

Share Price Information for Science Group (SAG)

Share Price is delayed by 15 minutes
Get Live Data
585.00    0.00 (0.00%)
Bid:
580.00
Ask:
590.00
Spread: 10.00 (1.724%)
Market Cap: £238.37m
SAG Live PriceLast checked at - London Stock Exchange

Intraday Science Group Share Chart

Trading Update, Board Changes and Dividend Policy

18 Oct 2012 07:00

RNS Number : 9506O
Sagentia Group PLC
18 October 2012
 



 

 

18 October 2012

 

Sagentia Group plc

 

("Sagentia", the "Company" or the "Group")

 

Trading Update, Board Changes and Dividend Policy

 

Trading Update

 

Operating performance over the summer period has continued broadly in line with the Board's expectations, as set out in the Interim Report. As a result, the Board anticipates a satisfactory operating outcome for the current financial year, before the one-off cost noted below.

 

The Group's balance sheet remains strong with unaudited shareholders funds at 30 September 2012 of £26.7 million, comprising mainly cash and freehold property, equivalent to approximately 69 pence per share. Net cash at 30 September 2012 was £13.2 million.

 

Board Changes

 

After three years at Sagentia, Brent Hudson, CEO, has decided to leave the company and resign as a director with effect from 31 October 2012. An associated one-off charge will be incurred in the current financial year. Brent has been instrumental in the turnaround of the Group and the Board wish him well for the future.

 

With immediate effect, the current Chairman, Martyn Ratcliffe, has been appointed as Executive Chairman. The Board does not anticipate appointing a plc Board replacement for Mr Hudson but is promoting Mick Withers and Dan Edwards, currently Head of the Medical and Commercial sectors respectively, to Joint Managing Directors of Sagentia Limited, the consultancy operating company.

 

Strategy & Dividend Policy

 

The restructuring in 2010 and 2011 established the required business processes within Sagentia's very talented science and engineering consultancy. As a result, Sagentia today is a successful, profitable business with a blue-chip customer base.

 

The Board continues to explore acquisition opportunities, but remains prudent, particularly in the current economic climate. However, a number of organic business growth opportunities have recently been identified which the Board believe could increase medium term growth. Therefore, whilst the Board will continue to target operating margins towards the upper quartile of comparable companies, in order to pursue these activities, the Board intends to balance the Group's operating margin targets with investment in longer term growth opportunities.

 

The Board has also determined that, subject to shareholder approval at the next Annual General Meeting, it is now appropriate to commence dividend payments. The Board anticipates a single dividend being paid each year.

 

- Ends -

 

For further information:

Sagentia Group plc

Martyn Ratcliffe, Executive Chairman

Tel: +44 (0) 1223 875 200

Neil Elton, Finance Director

www.sagentia.com

 

Numis Securities Limited

Nominated Adviser: Oliver Cardigan / Simon Willis

Corporate Broking: James Serjeant

Tel: +44 (0) 20 7260 1000

 

Media enquiries:

Abchurch

Henry Harrison-Topham

Tel: +44 (0) 20 7398 7702

henry.ht@abchurch-group.com

www.abchurch-group.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCGMMMGNNRGZZM
Date   Source Headline
13th Oct 20257:01 amRNSTrading Update
13th Oct 20257:00 amRNSTransaction in Own Shares
9th Oct 20257:00 amRNSTransaction in Own Shares
8th Oct 20257:01 amRNSTreasury shares issued & PDMR dealing
8th Oct 20257:00 amRNSTransaction in Own Shares
7th Oct 202512:00 pmRNSTreasury Shares Issued
7th Oct 20257:00 amRNSTransaction in Own Shares
6th Oct 20257:00 amRNSTransaction in Own Shares
3rd Oct 20257:00 amRNSTransaction in Own Shares
2nd Oct 20257:00 amRNSTransaction in Own Shares
1st Oct 20257:00 amRNSTotal Voting Rights
30th Sep 20257:00 amRNSHolding(s) in Company
29th Sep 202512:00 pmRNSTreasury shares issued
26th Sep 20257:00 amRNSTransaction in Own Shares
25th Sep 20257:00 amRNSTransaction in Own Shares
24th Sep 20257:01 amRNSTransaction in Own Shares
24th Sep 20257:00 amRNSTreasury shares issued
19th Sep 20257:00 amRNSTransaction in Own Shares
17th Sep 20257:00 amRNSTransaction in Own Shares
15th Sep 20257:00 amRNSTransaction in Own Shares
10th Sep 20257:00 amRNSTransaction in Own Shares
9th Sep 20257:00 amRNSTransaction in Own Shares
8th Sep 20257:00 amRNSTransaction in Own Shares
5th Sep 20257:01 amRNSHolding(s) in Company
5th Sep 20257:00 amRNSChairman Shareholding
2nd Sep 20252:20 pmRNSHolding(s) in Company
2nd Sep 20257:00 amRNSTransaction in Own Shares
1st Sep 20257:00 amRNSTotal Voting Rights
22nd Aug 20257:00 amRNSTransaction in Own Shares
21st Aug 20257:00 amRNSTransaction in Own Shares
20th Aug 20257:00 amRNSTransaction in Own Shares
19th Aug 20257:00 amRNSTransaction in Own Shares
18th Aug 20257:00 amRNSTransaction in Own Shares
15th Aug 20257:00 amRNSTransaction in Own Shares
13th Aug 20257:00 amRNSTransaction in Own Shares
12th Aug 20257:00 amRNSTransaction in Own Shares
11th Aug 20257:00 amRNSTransaction in Own Shares
8th Aug 20257:00 amRNSTransaction in Own Shares
7th Aug 20257:00 amRNSTransaction in Own Shares
4th Aug 20257:00 amRNSTransaction in Own Shares
1st Aug 20257:00 amRNSTransaction in Own Shares
31st Jul 20257:00 amRNSTransaction in Own Shares
28th Jul 20257:01 amRNSInterim results for 6 months ended 30 June 2025
28th Jul 20257:00 amRNSTransaction in Own Shares
24th Jul 20257:00 amRNSTransaction in Own Shares
18th Jul 20257:00 amRNSTransaction in Own Shares
16th Jul 20257:00 amRNSTransaction in Own Shares
15th Jul 20257:01 amRNSChange of Adviser & Notice of Interim Results
15th Jul 20257:00 amRNSTransaction in Own Shares
14th Jul 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.